Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.48 |
| ▸ | FEN1 | P39748 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 4/20 | 0.43 |
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14453645 | 0.85 | MAPT (0.48) | ALOX5APFEN1CNR2LMNAMAPT | |
| SCHEMBL31615928 | 0.83 | NPC1 (0.47) | ALOX5APFEN1F2RL3MAPT | |
| SCHEMBL5162273 | 0.82 | SCN9A (0.54) | ALOX5APFEN1MAPT | |
| SCHEMBL5163390 | 0.82 | SCN9A (0.54) | ALOX5APFEN1MAPT | |
| SCHEMBL5068253 | 0.82 | SCN9A (0.54) | ALOX5APFEN1MAPT | |
| SCHEMBL4372549 | 0.82 | ALOX5AP (0.48) | ALOX5APFEN1F2RL3 | |
| SCHEMBL4367186 | 0.82 | ALOX5AP (0.48) | ALOX5APFEN1F2RL3 | |
| SCHEMBL13419700 | 0.82 | ALOX5AP (0.51) | ALOX5APFEN1F2RL3 | |
| SCHEMBL4319486 | 0.81 | ALOX5AP (0.47) | ALOX5APFEN1MAPT | |
| SCHEMBL4320534 | 0.81 | ALOX5AP (0.47) | ALOX5APFEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191444-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191444-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191444-A1 | Benzimidazolyl derivatives | JAK1, MARK1, RAF1 | ALOX5AP 4621/4885FEN1 3430/4885CNR2 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.